GraniteShares 2x Long COIN Daily ETF vs Illumina, Inc. — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $4.84 (market cap $510.01M), while Illumina, Inc. trades at $268.39 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 78.3× GraniteShares 2x Long COIN Daily ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Illumina, Inc. for 83 Days on average.
| CONL | ILMN | |
|---|---|---|
Market Cap | $510.01M | $39.95B |
Volume | 21,041,836 | 3,169,503 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $293.69 |
52-Week Low | $3.93 | $91.00 |
Typical Hold Time | 15 Days | 83 Days |
Enterprise Value | — | $41.31B |
Signals from Pluang's Aura AI — not financial advice
CONL shares declined 7.76% to $5.23, reflecting significant bearish technical momentum with moving averages signaling strong selling pressure. The ETF faces headwinds from underlying asset volatility, with recent news highlighting substantial losses in the leveraged product structure. Technical indicators show oversold conditions with RSI at 24.76, suggesting potential for near-term bounce despite the dominant downtrend.
The outlook remains challenging given the leveraged ETF's inherent volatility and recent performance struggles. While oversold technicals may provide short-term relief, the product's structure exposes investors to amplified losses during market declines. Risk management is critical given the 2x leverage and concentrated exposure to cryptocurrency-related equities.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →